Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?

Peptide–drug conjugates (PDCs) are the next generation of targeted therapeutics drug after antibody–drug conjugates (ADCs), with the core benefits of enhanced cellular permeability and improved drug selectivity. Two drugs are now approved for market by US Food and Drug Administration (FDA), and in t...

Full description

Bibliographic Details
Published in:	Acta Pharmaceutica Sinica B
Main Authors:	Chen Fu, Lifeng Yu, Yuxi Miao, Xinli Liu, Zhaojin Yu, Minjie Wei
Format:	Article
Language:	English
Published:	Elsevier 2023-02-01
Subjects:	Peptide Drug Linker Targeted therapy Stability Permeability
Online Access:	http://www.sciencedirect.com/science/article/pii/S221138352200332X

Similar Items

Peptide–Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress
by: Krishna Jadhav, et al.
Published: (2025-04-01)

Current progress and remaining challenges of peptide–drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?
by: Dongyuan Wang, et al.
Published: (2025-04-01)

Research advances in peptide‒drug conjugates
by: Liming Gong, et al.
Published: (2023-09-01)

Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
by: Ruili Wang, et al.
Published: (2025-04-01)

Development of Methamphetamine Conjugated Vaccine through Hapten Design: In Vitro and In Vivo Characterization
by: Md Kamal Hossain, et al.
Published: (2023-02-01)

Advancements in antibody-drug conjugates as cancer therapeutics
by: Jung Yin Fong, et al.
Published: (2025-08-01)

Antibody–drug conjugates: Recent advances in linker chemistry
by: Zheng Su, et al.
Published: (2021-12-01)

Peptide-Drug Conjugates: A New Hope for Cancer Management
by: Vivek P. Chavda, et al.
Published: (2022-10-01)

Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
by: Chi Hun Song, et al.
Published: (2023-11-01)

Peptide Linker Affecting the Activity Retention Rate of VHH in Immunosorbents
by: Da Li, et al.
Published: (2020-11-01)

Antibody drug conjugates
by: Stalin Bala, et al.
Published: (2020-01-01)

Advances and Limitations of Antibody Drug Conjugates for Cancer
by: Candice Maria Mckertish, et al.
Published: (2021-07-01)

A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
by: Federico Riccardi, et al.
Published: (2023-09-01)

In silico decrypting of the bystander effect in antibody–drug conjugates for breast cancer therapy
by: Víctor L. Cruz, et al.
Published: (2025-08-01)

Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics
by: Florian Umstätter, et al.
Published: (2022-01-01)

Anti-Fungal Hevein-like Peptides Biosynthesized from Quinoa Cleavable Hololectins
by: Shining Loo, et al.
Published: (2021-09-01)

An Acid-Sensitive Bone Targeting Delivery System Carrying Acacetin Prevents Osteoporosis in Ovariectomized Mice
by: Xiaochen Sun, et al.
Published: (2022-12-01)

Introduction to Antibody-Drug Conjugates
by: Mark C. Pettinato
Published: (2021-10-01)

Switching Between Bicyclic and Linear Peptides — The Sulfhydryl-Specific Linker TPSMB Enables Reversible Cyclization of Peptides
by: Christoph Ernst, et al.
Published: (2018-10-01)

Smart Magnetic Drug Delivery Systems for the Treatment of Cancer
by: Angela Spoială, et al.
Published: (2023-02-01)

When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?
by: Chen Fu, et al.
Published: (2024-05-01)

A polymer-crosslinker-nanoparticles formulation for effective sand consolidation in loose sandstone formations
by: Mysara Eissa Mohyaldinn, et al.
Published: (2025-07-01)

Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody–Drug Conjugates for Cancer Therapy
by: Audrey Nathania Johan, et al.
Published: (2022-05-01)

Antibody–Drug Conjugates: The Last Decade
by: Nicolas Joubert, et al.
Published: (2020-09-01)

Progresses in research and development of antibody-drug conjugate
by: Wu Gang, et al.
Published: (2021-12-01)

Assessments of the In Vitro and In Vivo Linker Stability and Catabolic Fate for the Ortho Hydroxy-Protected Aryl Sulfate Linker by Immuno-Affinity Capture Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometric Assay
by: Byeong ill Lee, et al.
Published: (2021-01-01)

Recent advances in construction of small molecule-based fluorophore-drug conjugates
by: Wenjie Lang, et al.
Published: (2020-10-01)

Improved Antiglioblastoma Activity and BBB Permeability by Conjugation of Paclitaxel to a Cell‐Penetrative MMP‐2‐Cleavable Peptide
by: Dan Hua, et al.
Published: (2021-02-01)

How Far Have We Developed Antibody–Drug Conjugate for the Treatment of Cancer?
by: Yu Jun Lim, et al.
Published: (2023-05-01)

Antibody–Drug Conjugates for Cancer Therapy
by: Umbreen Hafeez, et al.
Published: (2020-10-01)

Conjugation of amiodarone to a novel cardiomyocyte cell penetrating peptide for potential targeted delivery to the heart
by: Ray Yurko, et al.
Published: (2023-07-01)

Peptide‐Drug Conjugate for Therapeutic Reprogramming of Tumor‐Associated Macrophages in Breast Cancer
by: Anni Lepland, et al.
Published: (2025-03-01)

Design of an in vivo cleavable disulfide linker in recombinant fusion proteins
by: Xiaoying Chen, et al.
Published: (2010-07-01)

Antibody–Drug Conjugates—A Tutorial Review
by: Stephanie Baah, et al.
Published: (2021-05-01)

Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy
by: Jakob Lindberg, et al.
Published: (2021-10-01)

Synthesis of Novel Carborane-Containing Derivatives of RGD Peptide
by: Alexander V. Vakhrushev, et al.
Published: (2023-04-01)

Peptide hydrogel-drug conjugates for tailored disease treatmentGuidelines to assemble peptide-based hydrogel-drug conjugates, referenced with a selection of relevant publications.
by: Thibault Cauwenbergh, et al.
Published: (2025-04-01)

Exploring Experimental and In Silico Approaches for Antibody–Drug Conjugates in Oncology Therapies
by: Vitor Martins de Almeida, et al.
Published: (2025-08-01)

Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs
by: Dan Wu, et al.
Published: (2025-10-01)

Peptide-Conjugated Nano Delivery Systems for Therapy and Diagnosis of Cancer
by: Isha Gaurav, et al.
Published: (2021-09-01)